证券日报网讯 8月29日晚间，梓橦宫发布公告称，近日，公司收到国家药品监督管理局核准签发的《受 理通知书》，公司在研产品硫酸氨基葡萄糖胶囊的境内生产药品注册上市许可申请获得受理。 （文章来源：证券日报） ...

据证券之星公开数据整理，近期博济医药(300404)发布2025年中报。截至本报告期末，公司营业总收入 3.61亿元，同比上升5.88%，归母净利润1556.99万元，同比下降48.33%。按单季度数据看，第二季度营 业总收入2.23亿元，同比上升27.95%，第二季度归母净利润1166.93万元，同比下降14.34%。本报告期 博济医药公司应收账款体量较大，当期应收账款占最新年报归母净利润比达565.35%。 本次财报公布的各项数据指标表现一般。其中，毛利率30.65%，同比减6.03%，净利率4.86%，同比减 46.3%，销售费用、管理费用、财务费用总计6177.39万元，三费占营收比17.09%，同比增0.8%，每股净 资产2.61元，同比增2.69%，每股经营性现金流0.06元，同比增342.15%，每股收益0.04元，同比减 48.42% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 3.41亿 | 3.61亿 | 5.88% | | 归母净利润（元） | 3013.51万 | 1556.99万 | ...

证券代码：300404 证券简称：博济医药 博济医药科技股份有限公司 投资者关系活动记录表 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 □业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | ■其他（投资者电话交流会） | | | 华创证券、兴业证券、招商证券、太平洋证券、东北证券、光大 | | 参与单位名称 | 证券、开源证券、银河证券、华安证券、华福证券、国泰海通、 | | 及人员姓名 | 西部利得、瑞丰基金、博远基金、富安达基金、瑞天投资、乾璐 | | | 投资、华宝基金、摩根资产、银河基金、长盛基金、招商基金等 | | 时间 | 年 月 日（星期三） 2025 8 27 | | 地点 | 广州 | | 上市公司接待 | 董事长、总经理：王廷春 | | 人员姓名 | 副总经理、董事会秘书：韦芳群 | | | 1、管理层介绍公司经营情况 2、交流互动环节： | | | 问题 1：请问目前公司临床 CRO 业务发展情况如何？订单价 | | | 格水平是否有所回暖？ | | 投资者关系活 动主要内容 | 答：2 ...

Core Viewpoint - The company announced that its wholly-owned subsidiary has received a drug registration acceptance notice for glucosamine sulfate capsules from the National Medical Products Administration of China [1] Company Summary - The drug is indicated for primary and secondary osteoarthritis and was first approved in Italy in 1982 and in China in 1996 [1] - The sales amount for the drug in domestic urban and county public hospitals, urban and online pharmacies, urban community hospitals, and township health centers is projected to be approximately 3.362 billion RMB in 2024 [1] - Currently, there are 13 companies in China that have obtained drug registration certificates for this product [1]

Group 1 - Vanke A announced the sale of 22 million A-share treasury stocks for a total of 146 million yuan, representing 0.18% of the company's total share capital, aimed at supplementing liquidity without impacting current profits [1] - Tencent Music plans to acquire 100% of Himalaya for a total consideration of $1.26 billion, which includes cash and shares, to expand its audio content ecosystem [1] - Dongfang Electric Heat signed a strategic cooperation agreement with Xiaomi's subsidiary to develop robotic electronic skin, focusing on flexible fabric pressure sensing applications [3] Group 2 - Chengdu Huamei launched a 4-channel, 12-bit, 16G high-precision RF direct sampling ADC chip, marking a significant breakthrough in high-speed data conversion technology [4] - Jinshi Technology clarified that it has not engaged in any business related to stablecoins, despite recent market interest, and noted a significant stock price increase of 76.51% over six trading days [5] - Xiantan Co. reported a 14.22% year-on-year increase in chicken product sales revenue for May, amounting to 469 million yuan [7]

Core Viewpoint - Tianjin Tianshili's wholly-owned subsidiary, Tianshili Shente, has received a drug registration certificate for Glucosamine Sulfate Capsules from the National Medical Products Administration, indicating a significant regulatory approval for a product aimed at treating primary and secondary osteoarthritis [1] Company Summary - The drug registration certificate for Glucosamine Sulfate Capsules is a key milestone for Tianjin Tianshili, enhancing its product portfolio in the pharmaceutical sector [1] - The indication for the drug is specifically for primary and secondary osteoarthritis, which addresses a significant market need [1]

Core Viewpoint - The announcement indicates that Boji Pharmaceutical (300404) has signed a technology transfer agreement with its subsidiary Guangzhou Huasheng Pharmaceutical Co., Ltd. and Shanxi Panlong Pharmaceutical Group Co., Ltd. for the transfer of technology related to "Glucosamine Sulfate Capsules" for a total fee of 4.5 million yuan, which is expected to positively impact the company's operating performance [1]. Group 1 - Boji Pharmaceutical and its subsidiary have entered into a technology transfer agreement with Panlong Pharmaceutical [1] - The total transfer fee for the technology is 4.5 million yuan [1] - Successful implementation of the transaction is anticipated to have a positive effect on the company's operating performance [1]